ArticleTranslational cancer research2025
The role of radiotherapy in distant nasopharyngeal carcinoma: a SEER analysis.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prior research, characterized by small patient cohorts, has yielded limited understanding of the effects of radiotherapy (RT) on distant nasopharyngeal carcinoma (dNPC). Therefore, we aim to examine the impact of RT on survival outcomes in dNPC utilizing a large-scale population database. Methods: Clinical data from 1,171 dNPC patients in the Surveillance, Epidemiology, and End Results (SEER) registry [2004-2019] was retrospectively analyzed. Among them, 227 (19%) did not receive RT, while 944 (81%) did. The primary outcome was overall survival (OS). Kaplan-Meier analysis was used to assess the survival of patients, and differences between treatment groups were evaluated using the Log-rank test and Cox's regression model. Nomogram was established to predict patient survival time and the model was evaluated using receiver operating characteristic (ROC) curves. Results: The median survival duration for all patients was 33 months, with a range spanning from 0 to 215 months. RT was associated with significantly improved OS [hazard ratio (HR): 0.35, 95% confidence interval (CI): 0.29-0.43, P<0.001]. According to the Cox proportional hazards model, the HR for patients who did not receive RT was 2.83 times higher compared to those who underwent RT. The nomograms for predicting 1-, 3-, and 5-year OS demonstrated moderately good calibration and discrimination, with a concordance index of 0.71. The areas under the curves (AUCs) of ROC for 1-, 3-, and 5-year OS were 0.762, 0.763, and 0.750 respectively. Conclusions: Our research revealed the significance of RT in the treatment of dNPC, and RT can serve as an independent predictor of survival, which might contribute to the creation of guidelines for dNPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.